Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels
- 1 April 2015
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 752, 1-7
Abstract
No abstract availableKeywords
Funding Information
- Catholic Medical Center Research Foundation
This publication has 24 references indexed in Scilit:
- Escitalopram block of hERG potassium channelsNaunyn-Schmiedeberg's Archives of Pharmacology, 2013
- Upregulation of ventricular potassium channels by chronic tamoxifen treatmentCardiovascular Research, 2010
- Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?European Journal of Cancer, 2009
- CYP2D6 and tamoxifen: DNA matters in breast cancerNature Reviews Cancer, 2009
- State-dependent block of HERG potassium channels byR-roscovitine: implications for cancer therapyAmerican Journal of Physiology-Cell Physiology, 2009
- Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cellsBiochemical Pharmacology, 2003
- Tamoxifen inhibits Na+and K+currents in rat ventricular myocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Tamoxifen (‘Nolvadex’): a reviewCancer Treatment Reviews, 2002
- QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experienceEuropean Journal of Clinical Pharmacology, 2000
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984